top of page

The Dutch Cancer Foundation (KWF) granted 1.25M to OralScreen to tackle the diagnostics challenges of oral-cavity cancers

20 apr. 2023

Cyclomics is collaborating with KWF, NWO, and Amsterdam UMC in the OralScreen consortium, led by Dr. J.B. Poell from VUMC, to revolutionize early detection of oral cavity cancers. The consortium aims to use non-invasive methods like mouthwashes and swabs to identify early DNA mutations, improving early diagnosis and decision-making for medical professionals.

Our technology, CyclomicsSeq, has been used in a recent Clinical Proof-of-Concept(Cpoc) project funded by the Oncode Institute. In this project several patients with advanced head and neck cancer were monitored over several months to obtain information about responders and non-responders for the given treatment. The project was performed in collaboration with the Netherlands Cancer Institute and the University Medical Center Utrecht.


Jeroen de Ridder says: “Based on the results obtained in this CPoC project, we were able to confidently set the next steps towards validating our technology in clinical practice. As a next step, we aim to include more patient samples to confirm these results in a larger study group.”


For more information please see:

https://www.oncode.nl/news/cell-free-dna-biomarkers-can-help-to-identify-treatment-responders-and-non-responders-of-head-and-neck-cancer-patients

bottom of page